AbCellera Biologics's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.18.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.66.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for AbCellera Biologics's EBIT per Share or its related term are showing as below:
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of AbCellera Biologics was 458.50% per year. The lowest was 458.50% per year. And the median was 458.50% per year.
ABCL's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.45 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
AbCellera Biologics (NAS:ABCL) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
AbCellera Biologics EBIT per Share Related Terms
AbCellera Biologics EBIT per Share Historical Data
* Premium members only.
The historical data trend for AbCellera Biologics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.66
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics (ABCL) has a EBIT per Share of $-0.66 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on AbCellera Biologics and its competitors. According to the industry distribution chart, AbCellera Biologics ranks #999999 out of 1184 companies in the Biotechnology industry.
Is AbCellera Biologics' EBIT per Share too high?
AbCellera Biologics' current EBIT per Share is $-0.66. Based on the distribution chart, AbCellera Biologics ranks #999999 out of 1184 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' EBIT per Share compare to SRPT and RAPP?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #999999 out of 1184 companies for EBIT per Share. This places AbCellera Biologics in the lower half of its industry. The industry median EBIT per Share is 15.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.45, based on 1,184 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on AbCellera Biologics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current EBIT per Share is $-0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.62, compared to a current price of $7.38 — trading 31.3% above its estimated fair value. The current EBIT per Share is $-0.66. AbCellera Biologics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current EBIT per Share is $-0.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $7.38 is trading 31.3% above its estimated GF Value™ of $5.62.
GuruFocus considers AbCellera Biologics to be Significantly Overvalued.
Key valuation signals for ABCL:
EBIT per Share: $-0.66
GF Value™: $5.62 vs. price of $7.38 (31.3% above fair value)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score
Get the complete analysis for ABCL
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 
